Non-Small Cell Lung Cancer (NSCLC) Market, by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global Non-Small Cell Lung Cancer (NSCLC) market size was estimated at USD 15.1 billion in 2023 and is projected to reach USD 28.3 billion in 2030 at a CAGR of 9.40% during the forecast period 2023-2030.
Non-small cell lung cancer is a type of lung cancer in which malignant tumor cells form in the lungs. It includes a group of different diseases that behave similarly, such as squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Adenocarcinoma is a type of non-small cell lung cancer that occurs more often in women than men and in young people than in the elderly. It is more common in people who have smoked and who have been exposed to polluted air more than those who smoke regularly. Squamous cell carcinoma is another common type of non-small cell lung cancer that is mostly caused by smoking. It occurs mostly in the middle part of the lungs, which is near the main airways. Large cell carcinoma can be more difficult to treat because it can be found anywhere in the lung and tends to spread more quickly than the other two.
The increasing number of patients suffering from non-small cell lung cancer worldwide is one of the major drivers for the growth of the market. This is mainly because there are more and more people in the world with unhealthy habits such as smoking, tobacco and alcohol consumption, high doses of nutritional supplements and sedentary lifestyles. In addition, the increase in air pollution is also one of the main factors affecting the increase in the number of sick people. According to statistics published by the World Health Organization (WHO) from February 2022, 2.2 million patients were diagnosed with lung cancer in 2020, and non-small cell lung cancer accounted for nearly 85% of all lung cancer patients. Thus, the availability of a large patient population and the increase in the number of patients with non-small cell lung cancer to treat patients has resulted in a high demand for the therapy.
The overall impact of COVID-19 pandemic remained negative for key players in the non-small lung cancer treatment market. The decline is due to decrease in number of patients diagnosed with non-small cell lung cancer in 2020 owing to lockdown restrictions along with disruption of supply chain during pandemic resulting in shortage of therapeutics.
The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. Non-small cell lung cancer accounts for 80-85% of all lung cancer cases worldwide, and this significant share of non-small cell lung cancer has led most of the major market leaders to focus on continuous innovation and increasing the effectiveness of advanced medicines and existing treatment methods. This is also due to the position of lung cancer as one of the most common cancers in the world and its impact on a significant number of deaths worldwide. Increasing diagnosis of non-small cell lung cancer and increased awareness of developed and developing markets in developed countries are also fueling the growth of the non-small cell lung cancer therapeutics market. This along with increasing R&D investments by key players and inclusion of non-small cell cancer drugs among key market players is also fueling market growth globally. These factors have led to the expansion of the market and increased demand for Non-Small Cell Lung Cancer (NSCLC) solutions.
North America to Dominate the Market